ZIVO Bioscience, Inc., a biotech and agtech innovator specializing in immune-boosting compounds derived from proprietary algal cultures, has launched a promising new partnership with one of the world’s top animal health companies. The collaboration marks a significant step toward transforming poultry disease management through non-antibiotic solutions.
Pioneering New Tools for Poultry Health
Under the agreement, the two companies will conduct independent studies to evaluate the efficacy of ZIVO’s biologic compounds in improving poultry immunity. While initially focused on poultry, the partnership may eventually extend to other livestock and companion animals.
The research aims to complement current vaccination strategies and address persistent diseases that hinder productivity in the global poultry industry.
“We’re excited to partner with a global animal health leader to scale our innovations,” said John Payne, Chairman and CEO of ZIVO Bioscience. “This collaboration allows us to pair our immune-modulating compounds with proven R&D infrastructure to bring disruptive, non-antibiotic solutions to market faster.”
Key Studies Target Coccidiosis and Viral Threats
1. Coccidiosis Challenge Study:
The first study is a 42-day challenge trial targeting coccidiosis, a widespread and costly parasitic disease in poultry. The trial will combine ZIVO’s compound with an existing commercial vaccine to test its ability to:
-
Enhance immune response
-
Improve overall bird health
-
Provide earlier protection during vulnerable growth stages
Data from this study will support ZIVO’s regulatory submissions to the USDA’s Center for Veterinary Biologics and strengthen its case for commercial deployment.
2. Viral Disease Study:
The second trial focuses on a viral poultry disease with high mortality and no current cure. Using a well-established in vivo model, researchers will examine how ZIVO’s compounds affect disease severity and transmission—particularly in cases resembling low-pathogenic avian influenza. Success in this trial could open doors to further studies on a broader range of viral threats.
Fully Funded Research with Global Potential
The unnamed animal health partner will fully fund both studies, bringing robust scientific and financial support to the effort. Researchers will explore how ZIVO’s compounds may:
-
Accelerate immunity post-vaccination
-
Protect birds during early life or high-stress periods
-
Reduce disease impact without antibiotics
-
Mitigate immune suppression from common infections
This project aligns with growing global demand for antibiotic-free disease control in livestock, driven by concerns over antimicrobial resistance and food safety.
Looking Ahead
ZIVO’s strategy positions its algae-derived biologics as a game-changer in animal health. If successful, the technology could redefine poultry disease prevention, offering scalable, natural alternatives to traditional antibiotics—and potentially reshape the wider livestock care landscape.
